GB201120779D0 - Cancer therapy - Google Patents

Cancer therapy

Info

Publication number
GB201120779D0
GB201120779D0 GBGB1120779.2A GB201120779A GB201120779D0 GB 201120779 D0 GB201120779 D0 GB 201120779D0 GB 201120779 A GB201120779 A GB 201120779A GB 201120779 D0 GB201120779 D0 GB 201120779D0
Authority
GB
United Kingdom
Prior art keywords
therapy
immunomodulator
ultrasound
cancer therapy
embolisation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1120779.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immodulon Therapeutics Ltd
Original Assignee
Immodulon Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immodulon Therapeutics Ltd filed Critical Immodulon Therapeutics Ltd
Priority to GBGB1120779.2A priority Critical patent/GB201120779D0/en
Publication of GB201120779D0 publication Critical patent/GB201120779D0/en
Priority to JP2014543984A priority patent/JP6085611B2/ja
Priority to US14/361,992 priority patent/US20140356397A1/en
Priority to BR112014012880A priority patent/BR112014012880A2/pt
Priority to CN201280059421.0A priority patent/CN104023733A/zh
Priority to EP12799260.0A priority patent/EP2785361B1/en
Priority to PCT/GB2012/052992 priority patent/WO2013079980A1/en
Priority to AU2012343536A priority patent/AU2012343536B2/en
Priority to RU2014121335A priority patent/RU2014121335A/ru
Priority to KR1020147016935A priority patent/KR20140097419A/ko
Priority to NZ624994A priority patent/NZ624994B2/en
Priority to SG11201402396XA priority patent/SG11201402396XA/en
Priority to CA2857429A priority patent/CA2857429A1/en
Priority to IN955MUN2014 priority patent/IN2014MN00955A/en
Priority to MX2014006511A priority patent/MX2014006511A/es
Priority to IL232890A priority patent/IL232890A0/en
Priority to US16/225,028 priority patent/US11318193B2/en
Priority to US16/916,194 priority patent/US11554166B2/en
Priority to US18/154,177 priority patent/US20230149525A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1120779.2A 2011-12-02 2011-12-02 Cancer therapy Ceased GB201120779D0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GBGB1120779.2A GB201120779D0 (en) 2011-12-02 2011-12-02 Cancer therapy
MX2014006511A MX2014006511A (es) 2011-12-02 2012-12-03 Tratamiento inmunogénico de cáncer.
RU2014121335A RU2014121335A (ru) 2011-12-02 2012-12-03 Иммуногенное лечение рака
NZ624994A NZ624994B2 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer
BR112014012880A BR112014012880A2 (pt) 2011-12-02 2012-12-03 tratamento imunogênico do câncer
CN201280059421.0A CN104023733A (zh) 2011-12-02 2012-12-03 癌症的免疫原性治疗
EP12799260.0A EP2785361B1 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer
PCT/GB2012/052992 WO2013079980A1 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer
AU2012343536A AU2012343536B2 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer
JP2014543984A JP6085611B2 (ja) 2011-12-02 2012-12-03 癌免疫療法
KR1020147016935A KR20140097419A (ko) 2011-12-02 2012-12-03 암의 면역원성 치료
US14/361,992 US20140356397A1 (en) 2011-12-02 2012-12-03 Immunogenic Treatment Of Cancer
SG11201402396XA SG11201402396XA (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer
CA2857429A CA2857429A1 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer
IN955MUN2014 IN2014MN00955A (enExample) 2011-12-02 2012-12-03
IL232890A IL232890A0 (en) 2011-12-02 2014-05-29 Immunogenic therapy for cancer
US16/225,028 US11318193B2 (en) 2011-12-02 2018-12-19 Immunogenic treatment of cancer
US16/916,194 US11554166B2 (en) 2011-12-02 2020-06-30 Immunogenic treatment of cancer
US18/154,177 US20230149525A1 (en) 2011-12-02 2023-01-13 Immunogenic treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1120779.2A GB201120779D0 (en) 2011-12-02 2011-12-02 Cancer therapy

Publications (1)

Publication Number Publication Date
GB201120779D0 true GB201120779D0 (en) 2012-01-11

Family

ID=45509083

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1120779.2A Ceased GB201120779D0 (en) 2011-12-02 2011-12-02 Cancer therapy

Country Status (15)

Country Link
US (4) US20140356397A1 (enExample)
EP (1) EP2785361B1 (enExample)
JP (1) JP6085611B2 (enExample)
KR (1) KR20140097419A (enExample)
CN (1) CN104023733A (enExample)
AU (1) AU2012343536B2 (enExample)
BR (1) BR112014012880A2 (enExample)
CA (1) CA2857429A1 (enExample)
GB (1) GB201120779D0 (enExample)
IL (1) IL232890A0 (enExample)
IN (1) IN2014MN00955A (enExample)
MX (1) MX2014006511A (enExample)
RU (1) RU2014121335A (enExample)
SG (1) SG11201402396XA (enExample)
WO (1) WO2013079980A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
CN105792883B (zh) 2013-12-05 2019-11-05 飞慕控股有限责任公司 利用射频电学膜击穿(rf-emb)的癌症免疫疗法
GB201322725D0 (en) * 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
EP3250142A4 (en) * 2015-01-30 2018-11-21 Rfemb Holdings LLC Radio-frequency electrical membrane breakdown for the treatment of tissues
PL3319635T3 (pl) 2015-06-24 2021-10-25 Immodulon Therapeutics Limited Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej
RU2596505C1 (ru) * 2015-07-02 2016-09-10 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ лечения онкологических больных цитотоксическими лимфоцитами
US10478194B2 (en) * 2015-09-23 2019-11-19 Covidien Lp Occlusive devices
JP7611642B2 (ja) 2016-01-15 2025-01-10 アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー がんの免疫学的処置
AU2017249500A1 (en) * 2016-04-14 2018-11-01 Feldreich Caro Ruiz AB An apparatus for use in irradiation therapy comprising ionization module and UV-light source
CA3058380A1 (en) 2017-03-28 2018-10-04 Emblation Limited Stenosis treatment
WO2019018813A1 (en) 2017-07-21 2019-01-24 Varian Medical Systems, Inc. METHODS OF USING ULTRA HIGH DOSE RATE RADIATION AND THERAPEUTIC AGENTS
RU2664597C1 (ru) * 2017-12-12 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения больных первично операбельным и местно-распространенным неоперабельным раком молочной железы
CN113164632A (zh) 2018-12-03 2021-07-23 融合制药公司 放射性免疫缀合物与检查点抑制剂组合疗法
US20220098578A1 (en) * 2019-01-31 2022-03-31 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
KR20220123033A (ko) * 2019-12-27 2022-09-05 제리아 신야쿠 고교 가부시키 가이샤 암 치료 방법 및 의약
EP4376945A1 (en) * 2021-07-27 2024-06-05 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy
CN114367060A (zh) * 2022-01-13 2022-04-19 深圳大学 激光交变电场联合治疗仪

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5207223A (en) 1990-10-19 1993-05-04 Accuray, Inc. Apparatus for and method of performing stereotaxic surgery
JPH06501479A (ja) * 1990-11-08 1994-02-17 スタンフオード・ルツク・リミテツド 抗原担体
US5458125A (en) 1994-01-28 1995-10-17 Board Of Directors Of The Leland Standford Jr. University Treatment planning method and apparatus for radiosurgery and radiation therapy
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
AU4281200A (en) 1999-04-23 2000-11-10 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
WO2003049751A1 (en) * 2001-12-10 2003-06-19 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
JP2006521090A (ja) 2002-07-12 2006-09-21 ザ ジョンズ ホプキンス ユニバーシティー メゾテリンワクチンおよびモデルシステム
AU2006306521B2 (en) 2005-10-21 2011-12-22 Medical College Of Georgia Research Institute, Inc. The induction of indoleamine 2,3-dioxygenase in dendritic cells by TLR ligands and uses thereof
US20080318252A1 (en) 2007-04-23 2008-12-25 Scott Kachlany Rapid assay to test anti-cancer drugs under physiological conditions
GB0526033D0 (en) 2005-12-21 2006-02-01 Bioeos Ltd Method
EP2010216A4 (en) * 2006-03-24 2010-06-09 Donald L Morton MYCOBACTERIAL IMMUNOTHERAPY FOR CANCER TREATMENT
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
DK2172211T3 (en) * 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
US8367075B2 (en) 2010-07-02 2013-02-05 Indian Institute Of Science Synergistic combination and method thereof
JP2014511396A (ja) * 2011-03-09 2014-05-15 ザ・ジョンズ・ホプキンス・ユニバーシティ 除去的放射線治療に使用される組成物およびその使用方法
US9132281B2 (en) 2011-06-21 2015-09-15 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
KR20140126357A (ko) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
US8617520B2 (en) 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy
GB201308325D0 (en) 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
EP3092004A4 (en) 2014-01-06 2017-02-22 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
PL3319635T3 (pl) 2015-06-24 2021-10-25 Immodulon Therapeutics Limited Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej
US20210299187A1 (en) 2018-06-25 2021-09-30 Immodulon Therapeutics Limited Cancer therapy

Also Published As

Publication number Publication date
IL232890A0 (en) 2014-07-31
US11318193B2 (en) 2022-05-03
SG11201402396XA (en) 2014-10-30
US20190224294A1 (en) 2019-07-25
IN2014MN00955A (enExample) 2015-04-24
EP2785361B1 (en) 2018-11-28
BR112014012880A2 (pt) 2017-06-13
RU2014121335A (ru) 2016-01-27
CN104023733A (zh) 2014-09-03
EP2785361A1 (en) 2014-10-08
AU2012343536B2 (en) 2017-08-24
KR20140097419A (ko) 2014-08-06
JP6085611B2 (ja) 2017-02-22
NZ624994A (en) 2016-10-28
MX2014006511A (es) 2014-12-05
WO2013079980A1 (en) 2013-06-06
JP2014533743A (ja) 2014-12-15
US20200338181A1 (en) 2020-10-29
AU2012343536A1 (en) 2014-06-05
US11554166B2 (en) 2023-01-17
US20230149525A1 (en) 2023-05-18
CA2857429A1 (en) 2013-06-06
US20140356397A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
MX2014006511A (es) Tratamiento inmunogénico de cáncer.
WO2011137449A3 (en) Method and apparatus for treatment of ocular tissue using combined modalities
Johnstone et al. Targeting the body to protect the brain: inducing neuroprotection with remotely-applied near infrared light
US20240123253A1 (en) Photodynamic therapy devices, systems and methods
WO2014153082A3 (en) Systems and methods for treating prostate cancer
JP2014533743A5 (enExample)
DK2288413T3 (da) Terapeutisk anlæg, som kombinerer stråleterapi og termoterapi
CN102670298A (zh) 广谱型肿瘤热疗设备
WO2013166504A3 (en) Targeted delivery of active agents using thermally stimulated large increase of perfusion by high intensity focused ultrasound
Yanase et al. Hyperthermia enhances the antitumor effect of photodynamic therapy with ALA hexyl ester in a squamous cell carcinoma tumor model
Huang et al. Therapeutical applications of heat in cancer therapy
Lloyd et al. Laser-Tissue Interactions
RU2010129236A (ru) Способ лечения местнораспространенных онкологических заболеваний в эксперименте
Jankun A thousand words about the challenges of photodynamic therapy: Challenges of photodynamic therapy
PH12015502086A1 (en) Ablative immunotherapy
Soni Heat transfer phenomenon and optical interaction during nanoparticle assisted thermal therapy
Soni et al. Spatiotemporal Temperature in a Tumor During Nanorod Assisted Thermal Therapy
LUO et al. Progress on Minimally Invasive Treatment of Localized Prostate Cancer
CA2722001A1 (en) Multi-maser ablation therapy (mmat)
HURWITZ 11.2 Hyperthermia for Prostate Cancer
MX2023012091A (es) Dispositivos y sistemas para terapia de ablacion.
Moretti et al. Conventional and unconventional use of lasers in skin disorders
CN204319538U (zh) 一种伽玛刀
Douplik Combined surgery and photodynamic therapy of cancer
SU et al. Mechanism of high intensity focused ultrasound thermal ablation therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)